Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830570 · ClinicalTrials.gov registry record
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
A clinical trial of Venous Thromboembolism and Vascular Diseases, sponsored by Medco Health Solutions.
- Completed
- Registry status
- 1,635
- Enrollment target
- 1
- Study location
NCT00830570: Completed study of Venous Thromboembolism and Vascular Diseases, sponsored by Medco Health Solutions.
NCT00830570 is a study of Venous Thromboembolism and Vascular Diseases that has completed, run by Medco Health Solutions. The registered enrollment target is 1,635 participants, below the 6,261-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00830570, a study of Venous Thromboembolism and Vascular Diseases, has completed, sponsored by Medco Health Solutions.
- COMPLETED
- Registry status
- 1,635 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.
Conditions Studied
Interventions
- OTHER CYP 2C9 and VKORC1 Testing for Warfarin
Study Locations (1)
New Jersey
- Medco Health Solutions, Inc. - Franklin Lakes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,635 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-01 |
What the finished NCT00830570 record still lists
NCT00830570 is an observational study that tracks outcomes without assigning an intervention. Its 1,635 participants enrollment target places it among the larger protocols in the corpus, below the 6,261-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (74% lower).
The record links to 7 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which CYP 2C9 and VKORC1 Testing for Warfarin is the first listed.
NCT00830570 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00830570 about?
NCT00830570 is a clinical study titled "The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings". The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.
What is the current status of trial NCT00830570?
This trial is currently completed. The enrollment target is 1,635 participants. The study started on 2007-07. Estimated completion is 2010-01.
What conditions does trial NCT00830570 study?
This clinical trial studies the following conditions: Venous Thromboembolism, Vascular Diseases, Thrombosis, Thromboembolism, Embolism and Thrombosis.
What interventions are being tested in trial NCT00830570?
The interventions under investigation include: CYP 2C9 and VKORC1 Testing for Warfarin (OTHER).
Who is sponsoring clinical trial NCT00830570?
This trial is sponsored by Medco Health Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00830570 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00830570's enrollment target sits among peer trials
1,635 16th of 47 higher than 32 of 47 other Venous Thromboembolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
RECRUITING
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
RECRUITING
-
Evaluation of the SCALED (SCaling AcceptabLE cDs)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia